The potential utility of PFKFB3 as a therapeutic target
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: It has been known for over half a century that tumors exhibit an increased demand for nutrients to fuel their rapid proliferation. Interest in targeting cancer metabolism to treat the disease has been renewed in recent years with the discovery that many cancer-related pathways have a profound effect on metabolism. Considering the recent increase in our understanding of cancer metabolism and the enzymes and pathways involved, the question arises as to whether metabolism is cancer's Achilles heel. Areas covered: This review summarizes the role of 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in glycolysis, cell proliferation, and tumor growth, discussing PFKFB3 gene and isoenzyme regulation and the changes that occur in cancer and inflammatory diseases. Pharmacological options currently available for selective PFKFB3 inhibition are also reviewed. Expert opinion: PFKFB3 plays an important role in sustaining the development and progression of cancer and might represent an attractive target for therapeutic strategies. Nevertheless, clinical trials are needed to follow up on the promising results from preclinical studies with PFKFB3 inhibitors. Combination therapies with PFKFB3 inhibitors, chemotherapeutic drugs, or radiotherapy might improve the efficacy of cancer treatments targeting PFKFB3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“tions, leading to increased glycolysis [10,11], as well as adaptive responses to the tumor microenvironment [12,13].”
BackgroundTIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019 · cited 3×
“TIGAR belongs to the histidine phosphatase family of proteins and its active site is structurally and functionally similar to that of FBPase-2 and phosphoglycerate mutase [30,32].”
BackgroundSelf-citationCancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505 · cited 1×
“tions, leading to increased glycolysis [10,11], as well as adaptive responses to the tumor microenvironment [12,13].”
BackgroundP53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Cantelmo, A. R., Conradi, L.-C., Brajic, A., Goveia, J., Kalucka, J., Pircher, A., Chaturvedi, P., Hol, J., Thienpont, B., Teuwen, L.-A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.006 · Cited by 659 · cited 1×
“Tumor vessel normalization via PFKFB3 inhibition also improved the delivery and efficacy of chemotherapy, thus providing a promising therapeutic strategy [93].”
BackgroundGlycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis
Xie, N., Tan, Z., Banerjee, S., Cui, H., Ge, J., Liu, R.-M., Bernard, K., Thannickal, V. J., & Liu, G. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0780oc · Cited by 582
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
Ruiz-García, A., Monsalve, E., Novellasdemunt, L., Navarro-Sabaté, À., Manzano, A., Rivero, S., Castrillo, A., Casado, M., Laborda, J., Bartrons, R., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190298 · Cited by 95 · cited 1×
“lipopolysaccharide (LPS), and adenosine [60], mitogenic lectin (concanavalin A) [61], phytohemagglutinin [62], and TGF-β1 [29] (Figure 3).”
BackgroundSelf-citationRegulation of 6-phosphofructo-1-kinase activity in ras-transformed rat-1 fibroblasts
Kole, H. K., Resnick, R. J., Van Doren, M., & Racker, E. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90084-v · Cited by 57 · cited 1×
“In addition, transformed cell lines and tumors present increased PFK-1 activity, which is activated by Ras and Src oncogenes [77,78], leading to increased levels of glycolysis in transformed cell lines [79].”
Background
Cited by
Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma
Feng, J., Li, J., Wu, L., Yu, Q., Ji, J., Wu, J., Dai, W., & Guo, C. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01629-4 · Cited by 699
Immunometabolism in the development of rheumatoid arthritis
Weyand, C. M., & Goronzy, J. J. (2020) · Immunological Reviews · doi:10.1111/imr.12838 · Cited by 193
Targeting glucose metabolism enzymes in cancer treatment: current and emerging strategies
Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B. (2022) · Cancers · doi:10.3390/cancers14194568 · Cited by 144
Zhao, J., Jin, D., Huang, M., Ji, J., Xu, X., Wang, F., Zhou, L., Bao, B., Jiang, F., Xu, W., et al. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1416472 · Cited by 84
Zhu, J., Yan, J., Zhang, Y., Zhu, X., & Chen, G. (2026) · Mammalian Genome · doi:10.1007/s00335-026-10202-x · Cited by 3
“It has been reported that PFKFB3 is overexpressed in various cancers, and its high expression and activity are closely associated with cancer aggressiveness and poor prognosis (Bartrons et al. 2018).”
Metadata
- Authors
- Bartrons, R., Rodríguez-García, A., Simon-Molas, H., Castaño, E., Manzano, A., & Navarro-Sabaté, À.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2018-07-16
- Volume
- 22
- Issue
- 8
- Pages
- 659-674
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2876613972
- Cited by
- 90
- References
- 9
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential utility of PFKFB3 as a therapeutic target. https://app.cochat.ai/papers/10.1080/14728222.2018.1498082
- The paper
- Bartrons, R., Rodríguez-García, A., Simon-Molas, H., Castaño, E., Manzano, A., & Navarro-Sabaté, À. (2018). The potential utility of PFKFB3 as a therapeutic target. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1498082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.